1 January 2022 in Academic Pediatrics
1 September 2021 in World Neurosurgery
14 November 2024 in Blood Advances
Few studies have prospectively evaluated the incidence and outcomes in children with provoked venous thromboembolism (VTE) and transient or persistent antiphospholipid antibodies (aPLs). We compared outcomes of patients aged <21 years with a first-episode acute provoked VTE and positive aPL at diagnosis, enrolled in the Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children trial. aPLs were tested at enrollment and, when positive, repeated at 6 weeks after VTE diagnosis. Subsequent testing was performed at the discretion of the treating hematologist. Of 524 patients, 116 (22%) had positive aPLs at enrollment. At follow-up, 70 (60%) had transient (n = 66) or low-titer aPLs (n = 4), 11 (10%) had persistent aPLs meeting the criteria for antiphospholipid antibody syndrome (APS), and 35 (30%) had no repeat testing. Patients with APS were older (15.8 vs 9.9 years; P = .014) and had a statistically significant higher risk of symptomatic recurrent VTE (18% vs 1%; odds ratio [OR], 12.2; 95% confidence interval [CI], 1.4-108; P = .025) and a statistically nonsignificant but clinically meaningful difference in the risk of anticoagulant-related clinically relevant bleeding (9% vs 0%; OR, 20.1; 95% CI, 0.7-558; P = .077) compared with those in the transient or low-titer aPL group. In conclusion, aPLs are common in young patients with acute provoked VTE and are mostly transitory and clinically insignificant. Patients with APS and provoked VTE appear to have an increased risk of recurrent VTE compared with patients with transitory or low-titer aPLs. Future collaborative studies should investigate the optimal VTE management for children with provoked VTE who meet the criteria for APS. The trial was registered at www.ClinicalTrials.gov as #NCT00687882.
19 February 2026 in Blood
Critically ill children are at a high risk for hospital-associated venous thromboembolism (HA-VTE). Developing a validated risk assessment model (RAM) to identify children who may benefit from thromboprophylaxis is essential. We aimed to prospectively validate the Children’s Healthcare Advancements in Thrombosis (CHAT)–intensive care unit (ICU) VTE RAM (CHAT-ICU RAM), containing 5 clinically significant variables: central venous catheter, immobility, congenital heart disease, autoimmune or inflammatory conditions, and hospital stay of ≥3 days in a multicenter cohort study. Randomly selected patients aged 0 to 21 years admitted to a pediatric ICU (PICU) at 32 institutions were monitored through medical record review for HA-VTE. Discrimination was assessed using the area under the receiver operating characteristic (AUROC) curve. Calibration was assessed using calibration plots. Complete-case and imputed analyses were performed, and model risk scores were generated along with posttest probability. The RAM was validated in 4674 patients, with an AUROC of 0.71, a calibration slope of 1.0, and an intercept of 1.81 × 10−5. The AUROC for the imputed model was 0.69 with a calibration slope of 1.03 and an intercept of 1.22 × 10−3. Calculated risk scores were 1 or 2 for each variable in the RAM with a total risk score ranging from 0 to 6. The estimated probability of developing HA-VTE ranged from 1% to 17.4% depending on the total score. In conclusion, the CHAT-ICU RAM has good discriminatory validity, is well calibrated, and reliably identifies children in the PICU at high and low risk of HA-VTE.